ClinicalTrials.gg
RecruitingNCT07529444Updated Oct 2, 2026

Microbiological Evaluation of the Effectiveness of Different Surface Decontamination Protocols for Dental Implants

An interventional study of Laser Photodynamic Therapy (PDT) and GalvoSurge Electrolytic Cleaning in Periimplant Diseases, Dental Implant Failure and Dental Implant Complications, sponsored by University of Zagreb. Recruiting at 1 site in Croatia. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by University of Zagreb · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 2, 2026Eligibility revisedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this prospective clinical study is to evaluate and compare the effectiveness of different cleaning (decontamination) methods for dental implants affected by peri-implantitis. Peri-implantitis is an inflammatory condition caused by a bacterial biofilm on the implant surface, which can lead to bone loss and implant failure if left untreated. Because the rough surface and threads of implants make them difficult to clean, finding the most effective decontamination method is critical for saving the implant.

This study will include 90 healthy, non-smoking participants who have a bone-level dental implant affected by peri-implantitis without vertical bone loss. Participants will be randomly assigned to one of three treatment groups (30 implants per group) to undergo a specific decontamination procedure during their surgical treatment:

Group 1 (Laser PDT): Decontamination using photodynamic therapy with a blue laser and riboflavin, followed by a sterile saline rinse.

Group 2 (GalvoSurge): Decontamination using an electrolytic cleaning device, followed by a sterile saline rinse.

Group 3 (Active Control): Decontamination using a 0.2% chlorhexidine gluconate rinse, which is the current standard of care.

To measure the effectiveness of these treatments, researchers will take sterile swabs from the implant surface immediately before and after the decontamination process. These swabs will be analyzed using PCR to detect changes in the microbiological load of five specific bacteria known to cause gum and implant disease (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Tannerella forsythia).

Following the decontamination and swabbing, all participants will receive a standard Guided Bone Regeneration (GBR) procedure using autogenous bone, a xenograft, and a collagen membrane to help rebuild the bone around the implant.

By comparing the microbiological results before and after treatment, the study aims to determine whether the newer methods (Laser PDT or electrolytic cleaning) are more effective at removing harmful bacteria than the traditional chlorhexidine rinse prior to bone regeneration.

Read the detailed description

Background and Rationale Contemporary dental implantology represents a reliable and predictable treatment method for partial or complete tooth loss. However, despite high success rates, complications such as peri-implantitis can lead to implant loss, significantly impacting patients functionally, emotionally, and financially. Peri-implantitis is an inflammatory condition affecting the soft and hard tissues surrounding an osseointegrated dental implant, with a prevalence of approximately 20% among patients undergoing implant therapy.

The primary etiological factor for peri-implantitis is the formation of a bacterial biofilm on the exposed surface of the implant. Biofilm formation is a complex, multi-step process involving the colonization of bacteria from around the implants, natural teeth, and other areas of the oral cavity. The oral biofilm associated with peri-implantitis is characterized by high microbial diversity. While no single specific bacterium has been identified as exclusively present in peri-implantitis biofilms, the long-term presence of this biofilm stimulates a host immune response, leading to chronic inflammation and subsequent tissue destruction.

The Clinical Challenge One of the most demanding and critical tasks in the treatment of peri-implantitis is the complete removal of the biofilm and the prevention of its recurrence. The presence of deep peri-implant pockets, restricted access to all implant surfaces, and the inherently rough, threaded topography of dental implants make mechanical and chemical decontamination exceptionally challenging.

Traditionally, mechanical tools such as curettes, sonic and ultrasonic instruments, air-polishing devices, and rotating titanium or chitosan brushes have been utilized to remove hard and soft deposits. A key clinical requirement is to achieve this with minimal damage or alteration to the implant surface. To address this, chemical agents (e.g., sterile saline, hydrogen peroxide, citric acid, EDTA, phosphoric acid, and chlorhexidine gluconate) are often employed alongside mechanical methods.

Recently, novel modalities have emerged to minimize surface damage while maximizing antimicrobial efficacy:

Antimicrobial Photodynamic Therapy (aPDT): Based on a photochemical reaction between a photosensitizer, oxygen, and a specific light wavelength, this therapy generates reactive oxygen species that induce bacterial cell death.

Electrolytic Cleaning (GalvoSurge): This method utilizes an electrolytic process to actively lift and eliminate bacterial biofilms from rough titanium surfaces, demonstrating promising in vitro results.

Study Objectives This prospective clinical trial is designed to evaluate and compare the antimicrobial efficacy of two novel implant decontamination protocols-Laser PDT and Electrolytic Cleaning (GalvoSurge)-against the widely accepted gold standard of 0.2% chlorhexidine gluconate rinsing. The primary focus is assessing the reduction of the microbiological load on the implant surface immediately following decontamination and prior to regenerative bone surgery.

Methodology and Clinical Protocol The study will be conducted at the School of Dental Medicine, University of Zagreb, within the Department of Oral Surgery. All surgical procedures will be performed by the same specialist in oral surgery to ensure procedural consistency.

The trial will enroll 90 bone-level dental implants affected by peri-implantitis but deemed viable for retention in the dental arch. Implants with vertical bone loss are excluded from this study. Eligible participants are restricted to healthy, non-smoking individuals classified as ASA I or II, with no systemic comorbidities. Pre-operative assessment will include Cone Beam Computed Tomography (CBCT) imaging.

The clinical workflow for each implant is as follows:

Flap Elevation: A mucoperiosteal flap is raised to expose the contaminated implant surface.

Baseline Sampling (Sample 1): A sterile swab is taken directly from the implant surface for initial PCR analysis to establish the baseline microbiological load.

Randomization and Intervention: Implants are randomly assigned to one of three treatment arms (n=30 per arm):

Group 1: Decontamination using Laser PDT (riboflavin photosensitizer + blue laser) followed by a sterile saline rinse.

Group 2: Decontamination using the GalvoSurge electrolytic system followed by a sterile saline rinse.

Group 3 (Active Control): Decontamination using a 0.2% chlorhexidine gluconate rinse.

Post-Treatment Sampling (Sample 2): Immediately following the decontamination protocol, a second sterile swab is taken for PCR analysis.

Regenerative Procedure: The surgery concludes with a classic Guided Bone Regeneration (GBR) procedure, utilizing autologous bone particles, a xenograft, and a collagen membrane fixed in place with titanium pins.

Microbiological Analysis

Samples will be analyzed using a validated real-time Polymerase Chain Reaction (RT-PCR) method targeting five specific periodontopathogenic bacteria:

Aggregatibacter actinomycetemcomitans

Porphyromonas gingivalis

Prevotella intermedia

Treponema denticola

Tannerella forsythia

The primary outcome is the change in the microbiological load. Results will be expressed as a semi-quantitative score (-, +, ++, +++), which will be numerically coded for statistical evaluation. The change is calculated as the difference between the post-treatment and pre-treatment values for each specific implant.

Sample Size and Statistical Analysis Plan The study is designed as a prospective comparative trial with repeated measures. Sample size estimations were based on available in vitro studies demonstrating a large effect size for electrolytic decontamination compared to standard methods.

Power Calculation: Assuming a conservative large standardized effect size (Cohen's d ≈ 0.9), a two-sided significance level of α = 0.05, and a test power of 80%, a minimum of 25 implants per group is required to detect statistically significant differences between the test groups and the control group. To account for potential sample loss or unusable swabs, the enrollment target was increased to 30 implants per group (90 implants total).

Data Analysis: Statistical significance is set at 95% (p \< 0.05). Normal distribution of the data will be assessed descriptively and via formal tests.

For normally distributed data, a one-way Analysis of Variance (ANOVA) will be utilized, followed by post-hoc comparisons of each test group against the control group.

If assumptions for parametric testing are not met, appropriate non-parametric alternatives will be applied.

Differences between baseline and post-treatment values within individual groups will be analyzed using tests for dependent samples.

Qualitative outcomes (e.g., the positive or negative presence of the target pathogens) will be evaluated using categorical data methodologies.

Hypothesis: Based on preliminary in vitro findings, the investigators anticipate a more pronounced therapeutic and antimicrobial effect in the GalvoSurge electrolytic cleaning group compared to the control.

02

Conditions studied

  • Periimplant Diseases
  • Dental Implant Failure
  • Dental Implant Complications

Browse trials for

Keywords

  • peri-implantitis
  • implant decontamination
  • PDT
  • electrolytic cleaning
  • GalvoSurge
  • Chlorhexidine Gluconate
03

In context

Peri-Implantitis

322 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.

This study's planned enrollment of 90 is above the median of 40 across 195 interventional studies indexed under Peri-Implantitis.

Browse Peri-Implantitis studies →

Lead sponsor

University of Zagreb is the lead sponsor of 71 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Systemically healthy patients classified as (no systemic comorbidities).
  • Patients who are non-smokers.
  • Clinical diagnosis of peri-implantitis on a single dental implant per patient.
  • Implant morphology classified as Monje Class Ia (buccal dehiscence with \<1mm horizontal bone loss) or Monje Class Ib (2-to-3-wall infrabony defect).
  • Dental implants of either "bone-level" or "tissue-level" design , featuring an exclusively SLA (Sandblasted, Large-grit, Acid-etched) surface in the subcrestal area requiring decontamination.
  • Implants deemed viable with a favorable perspective for long-term preservation in the dental arch.

Exclusion criteria

Exclusion Criteria :

  • Patients with any systemic comorbidities or those not classified as .
  • Patients who are currently smokers.
  • Presence of more than one implant affected by peri-implantitis in the same patient.
  • Implants featuring any surface morphology other than SLA (e.g., machined, hydroxyapatite-coated) in the treated subcrestal area.
  • Bone defect morphology that does not correspond to Monje Class Ia or Ib (e.g., severe horizontal or vertical bone loss outside these parameters).
  • Implants with a poor prognosis where extraction is indicated.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Laser PDT + Saline Rinse

    Implants in this group will undergo surface decontamination using Photodynamic Therapy (PDT). This involves the application of a riboflavin photosensitizer activated by a blue laser, followed by a rinse with sterile normal saline solution. The decontamination is performed immediately after the baseline microbiological swab (Sample 1) and before the post-treatment swab (Sample 2). All implants will subsequently receive a standard Guided Bone Regeneration (GBR) procedure. Interventions: Device / Procedure: Laser Photodynamic Therapy (PDT) Procedure: Guided Bone Regeneration (GBR)

    Device: Laser Photodynamic Therapy (PDT) · Procedure: Guided Bone Regeneration (GBR)

  • Experimental
    GalvoSurge + Saline Rinse

    Implants in this group will undergo surface decontamination using the GalvoSurge electrolytic cleaning system, followed by a rinse with sterile normal saline solution. The decontamination is performed immediately after the baseline microbiological swab (Sample 1) and before the post-treatment swab (Sample 2). All implants will subsequently receive a standard Guided Bone Regeneration (GBR) procedure. Interventions: Device / Procedure: GalvoSurge Electrolytic Cleaning Procedure: Guided Bone Regeneration (GBR)

    Device: GalvoSurge Electrolytic Cleaning · Procedure: Guided Bone Regeneration (GBR)

  • Active comparator
    Chlorhexidine Rinse (Control)

    Implants in this control group will undergo surface decontamination using the current clinical gold standard, which is a 0.2% chlorhexidine gluconate rinse. The decontamination is performed immediately after the baseline microbiological swab (Sample 1) and before the post-treatment swab (Sample 2). All implants will subsequently receive a standard Guided Bone Regeneration (GBR) procedure. Interventions: Drug / Procedure: 0.2% Chlorhexidine Gluconate Rinse Procedure: Guided Bone Regeneration (GBR)

    Drug: 0.2% Chlorhexidine Gluconate · Procedure: Guided Bone Regeneration (GBR)

Interventions

  • DeviceLaser Photodynamic Therapy (PDT)

    Antimicrobial photodynamic therapy applied to the contaminated implant surface. This involves the application of a riboflavin photosensitizer which is then activated by a blue laser to generate reactive oxygen species and eliminate bacterial biofilm. The procedure is concluded with a sterile normal saline rinse. Arm Group(s): Laser PDT + Saline Rinse

  • DeviceGalvoSurge Electrolytic Cleaning

    Decontamination of the implant surface using the GalvoSurge dental device. This system utilizes an electrolytic process with a specific cleaning solution to actively lift and detach the bacterial biofilm from the rough titanium surface. The procedure is concluded with a sterile normal saline rinse. Arm Group(s): GalvoSurge + Saline Rinse

  • Chemical decontamination of the implant surface by rinsing it thoroughly with a 0.2% chlorhexidine gluconate solution, which serves as the active control/gold standard for antimicrobial reduction. Arm Group(s): Chlorhexidine Rinse (Control)

  • ProcedureGuided Bone Regeneration (GBR)

    A classic surgical bone grafting procedure performed on all implants immediately following their assigned decontamination protocol. The procedure involves placing a mixture of autologous bone particles and a xenograft around the implant, which is then covered by a collagen membrane fixed in place using titanium pins. Arm Group(s): Laser PDT + Saline Rinse; GalvoSurge + Saline Rinse; Chlorhexidine Rinse (Control)

06

What researchers measure

Primary outcomes

  1. Change in Microbiological Load of Periodontopathogenic Bacteria

    The primary outcome evaluates the effectiveness of the decontamination protocols by measuring the change in the bacterial load on the implant surface. Sterile swabs taken before and after the intervention are analyzed using a validated real-time Polymerase Chain Reaction (RT-PCR) method to detect five specific periodontopathogenic bacteria (Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Treponema denticola, and Tannerella forsythia). The microbiological load is expressed as a semi-quantitative score (-, +, ++, +++), which is then numerically coded for statistical analysis. The primary measure is the calculated difference (change) between the post-treatment and baseline pre-treatment scores for each individual implant.

    Time frame: Intraoperatively: Measured immediately before the decontamination procedure (baseline) and immediately after the completion of the decontamination procedure (prior to bone regeneration).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Schlee M, Rathe F, Brodbeck U, Ratka C, Weigl P, Zipprich H. Treatment of Peri-implantitis-Electrolytic Cleaning Versus Mechanical and Electrolytic Cleaning-A Randomized Controlled Clinical Trial-Six-Month Results. J Clin Med. 2019 Nov 7;8(11):1909. doi: 10.3390/jcm8111909. PubMed 31703404 ↗
  • Takasaki AA, Aoki A, Mizutani K, Schwarz F, Sculean A, Wang CY, Koshy G, Romanos G, Ishikawa I, Izumi Y. Application of antimicrobial photodynamic therapy in periodontal and peri-implant diseases. Periodontol 2000. 2009;51:109-40. doi: 10.1111/j.1600-0757.2009.00302.x. No abstract available. PubMed 19878472 ↗
  • Ntrouka VI, Slot DE, Louropoulou A, Van der Weijden F. The effect of chemotherapeutic agents on contaminated titanium surfaces: a systematic review. Clin Oral Implants Res. 2011 Jul;22(7):681-690. doi: 10.1111/j.1600-0501.2010.02037.x. Epub 2010 Dec 29. PubMed 21198891 ↗
  • Monje A, Pons R, Insua A, Nart J, Wang HL, Schwarz F. Morphology and severity of peri-implantitis bone defects. Clin Implant Dent Relat Res. 2019 Aug;21(4):635-643. doi: 10.1111/cid.12791. Epub 2019 May 14. PubMed 31087457 ↗
  • Mombelli A, Decaillet F. The characteristics of biofilms in peri-implant disease. J Clin Periodontol. 2011 Mar;38 Suppl 11:203-13. doi: 10.1111/j.1600-051X.2010.01666.x. PubMed 21323716 ↗
  • Berglundh T, Armitage G, Araujo MG, Avila-Ortiz G, Blanco J, Camargo PM, Chen S, Cochran D, Derks J, Figuero E, Hammerle CHF, Heitz-Mayfield LJA, Huynh-Ba G, Iacono V, Koo KT, Lambert F, McCauley L, Quirynen M, Renvert S, Salvi GE, Schwarz F, Tarnow D, Tomasi C, Wang HL, Zitzmann N. Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun;45 Suppl 20:S286-S291. doi: 10.1111/jcpe.12957. PubMed 29926491 ↗

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Eligibility
Criteria largely rewritten (15 changes)
What changed in the criteria
Inclusion criteria
  • RemovedPatients presenting with at least one bone-level dental implant affected by peri-implantitis.
  • AddedSystemically healthy patients classified as ASA I (no systemic comorbidities).
  • EditedPatients must bewho are non-smokers.
  • RemovedPatients in good general health, classified as ASA I (a normal healthy patient) or ASA II (a patient with mild systemic disease) according to the American Society of Anesthesiologists physical status classification system.
  • AddedClinical diagnosis of peri-implantitis on a single dental implant per patient.
  • AddedImplant morphology classified as Monje Class Ia (buccal dehiscence with <1mm horizontal bone loss) or Monje Class Ib (2-to-3-wall infrabony defect).
  • AddedDental implants of either "bone-level" or "tissue-level" design , featuring an exclusively SLA (Sandblasted, Large-grit, Acid-etched) surface in the subcrestal area requiring decontamination.
  • EditedThe affected implant must beImplants deemed viable with a favorable perspective for long-term preservation/retention in the dental arch.
Exclusion criteria
  • RemovedPresence of vertical bone loss around the affected implant.
  • RemovedImplants that are not bone-level (e.g., tissue-level implants).
  • EditedPatients with any systemic comorbidities or those not classified as ASA I.
  • AddedPresence of more than one implant affected by peri-implantitis in the same patient.
  • AddedImplants featuring any surface morphology other than SLA (e.g., machined, hydroxyapatite-coated) in the treated subcrestal area.
  • AddedBone defect morphology that does not correspond to Monje Class Ia or Ib (e.g., severe horizontal or vertical bone loss outside these parameters).
  • EditedImplants with a poor prognosis that cannot be preserved in the dental archwhere extraction is indicated.
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Eligibility Criteria largely rewritten (15 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients presenting with at least one bone-level dental implant affected by peri-implantitis.
    • AddedSystemically healthy patients classified as ASA I (no systemic comorbidities).
    • EditedPatients must bewho are non-smokers.
    • RemovedPatients in good general health, classified as ASA I (a normal healthy patient) or ASA II (a patient with mild systemic disease) according to the American Society of Anesthesiologists physical status classification system.
    • AddedClinical diagnosis of peri-implantitis on a single dental implant per patient.
    • AddedImplant morphology classified as Monje Class Ia (buccal dehiscence with <1mm horizontal bone loss) or Monje Class Ib (2-to-3-wall infrabony defect).
    • AddedDental implants of either "bone-level" or "tissue-level" design , featuring an exclusively SLA (Sandblasted, Large-grit, Acid-etched) surface in the subcrestal area requiring decontamination.
    • EditedThe affected implant must beImplants deemed viable with a favorable perspective for long-term preservation/retention in the dental arch.
    Exclusion criteria
    • RemovedPresence of vertical bone loss around the affected implant.
    • RemovedImplants that are not bone-level (e.g., tissue-level implants).
    • EditedPatients with any systemic comorbidities or those not classified as ASA I.
    • AddedPresence of more than one implant affected by peri-implantitis in the same patient.
    • AddedImplants featuring any surface morphology other than SLA (e.g., machined, hydroxyapatite-coated) in the treated subcrestal area.
    • AddedBone defect morphology that does not correspond to Monje Class Ia or Ib (e.g., severe horizontal or vertical bone loss outside these parameters).
    • EditedImplants with a poor prognosis that cannot be preserved in the dental archwhere extraction is indicated.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07529444
Lead sponsor
University of Zagreb
Responsible party
Igor Smojver (Sinior assistant, University of Zagreb) — Principal investigator
First posted
Apr 14, 2026
Start date
Mar 1, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Igor Smojver, DMD;PhD
Contact
ismojver@sfzg.hr
385981651932

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion